F ueled by the hepatitis C and fatty liver disease epidemics, the incidence of hepatocellular carcinoma (HCC) is projected to increase for at least another decade in the United States. 1 With HCC becoming a leading indication for liver transplant (LT), 2, 3 there have been ongoing efforts by the transplant community to refine LT selection criteria to ensure good outcome while attempting to meet growing demands. The Milan criteria (1 lesion 5 cm, 2-3 lesions 3 cm) 4 have been the benchmark for the selection of candidates with HCC for LT for 2 decades. 5 There have been several proposals to expand tumor size limits modestly beyond Milan criteria, 6 including the University of California, San Francisco criteria 7 and the "up-to-7" criteria, 8 both associated with an estimated 5-year post-transplant survival only slightly below that with the Milan criteria. One of the limitations of expansion of the limits in tumor size/number alone is that it does not account for the effects of local regional therapy (LRT), which has been widely used to control tumor growth as a bridge to LT, particularly if the waiting time is prolonged. 5 Tumor down-staging, defined as a reduction in tumor burden using LRT to meet acceptable criteria for LT, 9 has been identified as one of the priorities for research in 2 national conferences on HCC. 10, 11 Down-staging is an attractive alternative to simply expanding the tumor size limits because response to down-staging treatment may also serve as a prognostic marker and a tool to select a subgroup of patients with more favorable tumor biology who will likely do well after LT. 9 Although published results on tumor down-staging before LT are encouraging, they are based entirely on single-center experience. [12] [13] [14] [15] In this first multicenter study, we aimed to assess post-LT and intention-to-treat outcomes under a uniform down-staging protocol. We also aimed to assess factors associated with treatment failure, which may help refine inclusion criteria for down-staging and improve overall outcome.
Methods

Down-Staging Protocol
The United Network for Organ Sharing (UNOS) Region 5 down-staging protocol adopted from University of California, San Francisco has previously been described in detail (Table 1) . 12 The present study included consecutive adult HCC patients enrolled in the down-staging protocol at 3 LT centers in Region 5 (University of California, San Francisco, California Pacific Medical Center, and Scripps Green Hospital) from 2002-2012. A minimum follow-up of 6 months after the first down-staging treatment was required for inclusion. The diagnosis of HCC for a lesion 1 cm was based on either quadruple-phase computed tomography or magnetic resonance imaging with gadolinium contrast showing arterial phase enhancement and washout during the delayed images, or if a lesion showed interval growth. Hepatic nodules <1 cm were not counted as HCC.
The specific type of LRT used was at the discretion of each of the 3 center's multidisciplinary tumor board based on a review of imaging studies and not prespecified in the down-staging protocol. All patients included in the down-staging protocol underwent computed tomography or magnetic resonance imaging of the abdomen at 1 month after each LRT, and at a minimum of once every 3 months. Imaging criteria for successful down-staging included a decrease size of the tumors to within Milan criteria, or complete tumor necrosis with no contrast enhancement. Response to treatment was based on radiographic measurements of the maximal diameter of viable tumors, not including the area of necrosis resulting from LRT. 9 Each center applied LRT with repetitive interventions if needed to achieve 
Histopathologic Analysis
In patients who underwent LT after successful down-staging, explant histopathologic features evaluated included tumor size, number of tumor nodules, histologic grade of differentiation based on the Edmondson and Steiner criteria, 16 and the presence of microvascular or macrovascular invasion. Pathologic tumor staging of viable tumors was based on the UNOS TNM staging system. 9 
Outcomes
The primary outcome was probability of treatment failure. Treatment failure was defined as dropout from the down-staging protocol because of tumor progression, liver-related death without LT, or post-LT HCC recurrence. The principle of down-staging is to select a subgroup of patients who are likely to demonstrate response to tumor down-staging and also do well after LT with a low risk of tumor recurrence. Defining treatment failure in this way allows for the identification of patients who would benefit the most from down-staging. Secondary outcomes included probability of successful downstaging, intention-to-treat survival, and post-LT HCC recurrence and survival. Follow-up time was censored at the first of post-LT death, last follow-up, or 5 years after LT. For patients who developed a nonliver disease medical contraindication to LT, were no longer interested in undergoing LT, or were noncompliant with each center's transplant policies, follow-up was censored at the time of delisting or removal from the protocol.
Statistical Analysis
The chi-square and Mann-Whitney U tests were used to assess differences between subgroups. Kaplan-Meier methods were used to estimate survival functions, cumulative probabilities, and 95% confidence intervals (CI). Subgroup and center comparisons were evaluated using the log-rank test. To determine characteristics associated with treatment failure, univariate logistic regression evaluated the likelihood of never achieving down-staging and estimated odds ratios and 95% CIs. The association of explanatory variables was explored using univariate and multivariable hazard ratios (HR) and 95% CIs estimated by competing risks for post-LT HCC recurrence and Cox proportional hazards regression for treatment failure. To categorize continuous variables, multiple cutoffs were tested and evaluated using Akaike information criteria with lower Akaike information criteria values indicating better model fit. Explanatory variables with a univariate P value <.1 were included in the multivariable analysis with the final model selected by backward elimination (P for removal >.05).
Results
Baseline Characteristics and Local Regional Therapy
The baseline characteristics and details of LRT are presented in Table 2 . Most of the cohort (69.5%) was from Center 1. At the time of first down-staging procedure, median MELD was 10, a total of 57.5% were Child's class A (Child-Turcotte-Pugh [CTP] 5-6), 31.8% were Child's B (CTP 7-9), and 10.6% were Child's C (CTP 10-15). There were 38.0% with a single lesion, 51.3% with 2-3 lesions, and 10.7% with 4-5 lesions. Median baseline alphafetoprotein (AFP) was 24 (interquartile range [IQR], 8-154) and 10.2% had an AFP 1000 ng/mL. There was a similar distribution of LRT received with 25.7% undergoing a single procedure and 26.2% requiring 4 LRTs. Transarterial chemoembolization (TACE) was the mainstay of LRT with 50.3% receiving TACE alone and 43.3% receiving a combination of TACE and radiofrequency ablation. There were no significant differences among the 3 centers in baseline characteristics or type and number of LRT received.
Intention-to-Treat Outcome
The intention-to-treat outcome is summarized in Figure 1 and stratified by study center in Table 3 . Overall, 31 patients (16.6%) were never down-staged to within Milan criteria and dropped out after a median of 4.2 months from first LRT (IQR, 1.3-7.2). Among them, 13 (41.9%) received only 1 LRT before tumor progression. In logistic regression analysis, the only factor predicting inability to ever achieve tumor down-staging was pretreatment AFP 100 (odds ratio, 2.7; P ¼ .02) and AFP 1000 (odds ratio, 3.8; P ¼ .01). The probability of not being able to be down-staged was 33.0% in those with an AFP 1000 compared with 15.2% for AFP 100-999 and 9.3% for AFP <100 (P ¼ .03). Number and size of tumors, MELD score, Child's class, and number of LRT were not significant predictors of inability to be down-staged.
Successful down-staging to within Milan criteria was achieved in 156 patients (83.4%) after a median of 2.7 months (IQR, 1.4-4.9). Among them, 67.9% were down-staged after a single LRT, whereas 32.1% required multiple treatments. The cumulative probability of successful down-staging from first LRT was 35.5% at 2 months, 74.5% at 6 months, and 86.4 at 12 months.
Of the 156 patients initially down-staged, 28 (17.9%) experienced waitlist dropout because of subsequent tumor progression and 9 (5.8%) had liver-related death without LT. The median time from listing with MELD exception to dropout in these 37 patients was 6.2 months (IQR, 3.2-10.8). Successful down-staging to Milan criteria was maintained for >3 months in 75.7% and >6 months in 56.7%, before tumor progression and removal from the waiting list.
At last follow-up, 109 patients (58.3% of the entire cohort) had received LT and 10 patients were still active on the waiting list. The median time from MELDexception listing after successful down-staging to LT was 12.6 months (IQR, 5.8-18.6). Of the 109 LT recipients, 3 (2.8%) received live donor LT (all at center 1) at 3-4.8 months after achieving successful downstaging. The Kaplan-Meier intention-to-treat survival at 1 and 5 years from first down-staging procedure was 84.3% and 55.4%. Intention-to-treat survival at 1 year from first down-staging procedure was 37.6% in those never able to be down-staged, 72.9% in those who dropped out after initial successful down-staging, and 100% in those who underwent LT (P < .001). There were no center-specific differences in intention-to-treat survival (Figure 2A ).
Explant Histopathologic Characteristics
Complete tumor necrosis from LRT (no residual tumors in explant) was observed in 34.9%. Tumor stage was within Milan criteria (T1/T2) in 45.9%, and beyond Milan criteria (T3/T4) in 19.3% because of understaging by imaging. The latter group included 1 patient with macrovascular invasion (T4b) and 1 with lymph node invasion (N1). Only 6.4% had microvascular invasion. Among 71 patients with viable tumors, almost all Of the 106 patients with hepatitis C infection, none had received direct-acting antiviral agents before liver transplant; 62% were genotype 1 and 23% were genotype 3. Overall, 41% had positive hepatitis C RNA at the time of liver transplant.
had either well-differentiated (35.2%) or moderately differentiated tumors (63.4%), and only a single patient (1.4%) had poorly differentiated tumor grade. There were no center-specific differences in explant histologic characteristics.
Post-transplant Survival and Hepatocellular Carcinoma Recurrence
Median post-LT follow-up was 4.3 years (IQR, 2.4-6.6). The Kaplan-Meier post-LT survival at 1 and 5 years was 94.5% and 79.7%. There were no centerspecific differences in post-LT survival ( Figure 2B ). HCC recurrence developed in 11 patients (10.1%) at a median of 19.1 months (IQR, 7.3-31.7) from LT. The Kaplan-Meier recurrence-free probability at 1 and 5 years after LT was 95.4% and 87.3%. The recurrencefree probability at 5 years after LT was not significantly different between centers (87% in center 1 and 88.9% in centers 2 and 3 combined; P ¼ .99). Predictors of post-LT HCC recurrence on competing risks multivariable analysis included AFP >500 ng/mL (HR, 8.41; 95% CI, 2.02-35.64; P ¼ .003) and vascular invasion on explant (HR, 7.37; 95% CI, 1.48-37.34; P ¼ .02). Wait time from first down-staging treatment to LT, number or type of LRT, center, and explant grade and stage were not significant predictors of HCC recurrence.
Treatment Failure
A total of 79 patients (42.2%) were classified as treatment failures (Figure 1 ). Kaplan-Meier probability of Figure 1 . Summary of the intention-to-treat outcome of the 187 patients enrolled in the downstaging protocol. treatment failure at 1 and 5 years from first downstaging treatment was 25.3% and 44.3%. There were no center-specific differences in probability of treatment failure (P ¼ .53). In univariate analysis, significant predictors of treatment failure included pretreatment AFP 20 ng/mL, with increasing HRs for increasing baseline AFP values. There was a nonsignificant trend toward increased treatment failure for patients with Child's B/C cirrhosis and increasing MELD score. In multivariable analysis, pretreatment AFP 1000 ng/mL (HR, 3.25; P < .001) and Child's B/C cirrhosis (HR, 1.61; P < .001) remained statistically significant predictors of treatment failure (Table 4) .
Patients with Child's B/C cirrhosis (n ¼ 76) had Kaplan-Meier 1-and 5-year probability of treatment failure of 33.1% and 50.8% compared with 18.5% and 38.9% for patients with Child's A cirrhosis (n ¼ 103; P ¼ .06). To determine the reason behind the association between Child's B/C cirrhosis and treatment failure, we evaluated tumor-and treatment-related variables based on Child's class. We found no significant interactions between Child's class and AFP, number of lesions, number of LRTs received, or median time to dropout from first down-staging procedure. None of the 31 Child's A patients who dropped out had hepatic decompensation after LRT compared with 19.2% (5/26) of Child's B patients and 36.4% (4/11) of Child's C patients (P ¼ .005). Of the 19 patients with a pretreatment AFP 1000 ng/mL, 6 were never able to be down-staged, 7 dropped out because of tumor progression after initial down-staging, and 1 had successful down-staging but was ultimately not considered for LT because of psychosocial contraindications. Only 5 patients with a pretreatment AFP 1000 underwent LT and 2 of these experienced post-LT HCC recurrence. These 2 patients had an AFP at LT of 32 and 473 compared with an AFP <4 ng/mL in the 3 patients without HCC recurrence. Kaplan-Meier 1-and 5-year probabilities of treatment failure were 63.9% and 75.9% for patients with a baseline AFP 1000 compared with 20.2% and 39.8% among patients with a pretreatment AFP <1000 (P < .001).
Patients with both AFP 1000 ng/mL and Child's B/C cirrhosis had a 70.4% risk of treatment failure at 1 year from first down-staging procedure as compared with 31.7% with 1 risk factor and 14.4% without either risk factor (P ¼ .001). Patients with both risk factors had a 100% treatment failure rate within 2 years. In contrast, the probability of treatment failure at 5 years was 46.2% in patients with 1 of the 2 risk factors and 36.5% for those with neither risk factor (P ¼ .001) (Figure 3 ).
Discussion
In recent years there has been a paradigm shift in the selection of HCC patients for LT. [17] [18] [19] Rather than relying solely on tumor size and number, there has been a greater emphasis on incorporating markers of tumor biology, including AFP 20, 21 and response to LRT, [22] [23] in the selection scheme. In this context, high AFP and tumor progression despite LRT identify more aggressive tumors with a substantially greater risk for HCC recurrence after LT. A period of observation is required for evaluating tumor response to LRT and changes in AFP before LT. This concept has been filtered into the "ablate and wait" strategy for candidate selection. 17 Tumor down-staging is a process that combines expanded criteria with response to LRT. 9 It has been consistently shown that a subset of patients with initial tumor burden exceeding Milan criteria could achieve post-LT outcomes similar to that with Milan criteria. Identifying those who will likely do well after LT based on response to LRT with reduction in tumor burden to within Milan criteria underlies the fundamental principle behind using down-staging as an additional selection tool for LT. 9 Additionally, given that demand for organs far exceeds supply and the importance of maximizing transplant survival benefit, patients who are successfully down-staged with LRT may be more appropriate LT candidates than those with a single 2-to 3-cm well-treated tumor and a low risk for waitlist dropout. 24 One of the criticisms of the downstaging evidence is that it is based entirely on singlecenter studies, 9,15 and may not be reproducible on a broader scale. In this first multicenter study on tumor down-staging using a uniform protocol from Region 5, we observed excellent overall 5-year post-LT survival of 80% and recurrence-free probability of 87%, and a very low likelihood of unfavorable histologic features in the explant. Only 7% had microvascular or macrovascular invasion, and only 1 patient had poorly differentiated tumor grade. These findings underscore the effectiveness of down-staging in selecting tumors with favorable biology and a good prognosis for LT. Importantly, we did not observe significant center effects in the intention-to-treat survival, post-LT survival, or HCC recurrence. One of the objectives of this multicenter study was to assemble a large enough cohort to assess factors associated with treatment failure, which might help refine inclusion criteria for down-staging. The 2 factors predicting treatment failure were pretreatment AFP 1000 ng/mL and Child's class B/C cirrhosis. Of the 19 patients with a baseline AFP 1000 ng/mL, only 3 (16%) underwent LT after successful down-staging and did not experience post-LT HCC recurrence. This adds to the mounting evidence of high AFP as a poor prognostic marker for LT, both in terms of waitlist outcome 24 and post-LT survival and HCC recurrence. 20, 21 With respect to the influence of Child's class on waitlist dropout, patients with Child's B/C cirrhosis likely have fewer LRT options and receive less aggressive treatments given the concerns of hepatic decompensation following LRT when compared with those with Child's A cirrhosis. Additionally, Child's B/C patients are more likely to have liverrelated death without LT regardless of whether they receive LRT.
Given that treatment failure was observed in all Child's B/C patients with pretreatment AFP 1000 ng/mL, these patients should be excluded from down-staging and not be subjected to the risks attendant on LRT, particularly hepatic decompensation or even death. For patients with Child's A cirrhosis and a high baseline AFP 1000 ng/mL, we propose following the previous recommendation of a reduction in the AFP level to <500 ng/mL after LRT to be eligible for LT. 9, 10 This is also in accordance with a recently approved UNOS national policy for HCC MELD-exception listing. 25 We have further demonstrated that AFP >500 ng/mL predicted HCC recurrence after LT.
A recent systematic review and pooled analysis by Parikh et al 15 showed an aggregate down-staging success rate of 54% after excluding patients with tumor thrombus, but there are major differences in the definition of success rate in these studies. In the present series, 58% of the patients received LT, but 83% of the entire cohort was initially successfully down-staged to within Milan criteria. This high initial success rate of downstaging is likely related to the upper limits in tumor size and number for inclusion. Only 1 other study on down-staging defined the upper limits in tumor burden. Ravaioli et al 13 used more liberal inclusion criteria for down-staging and showed a successful down-staging rate of 69%, but the 3-year recurrence-free survival after LT was only 71%. Rassiwala et al 26 demonstrated a very low probability of LT of 12% when applying an "all-comers" down-staging protocol to patients with initial tumor burden exceeding Region 5 down-staging inclusion criteria. All these findings suggest that there 
